Floatz logo

Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
ab-201
Breast Cancer
GC Cell CorporationP1/2CC (44)
Abemaciclib
Central Nervous System Disorder
Stemline Therapeutics, Inc.P1/2CC (44)
Abemaciclib
Malignant Glioma
Tango Therapeutics, Inc.P1/2CC (44)
Abemaciclib
Rectal Cancer
M.D. Anderson Cancer CenterP1/2CC (44)
Acalabrutinib
Glioblastoma
Acerta Pharma BVP1/2CC (44)
Acetazolamide
Schizoaffective Disorder
Vishwajit Nimgaonkar, MD PhDP1/2CC (44)
ak119
Non-Small Cell Lung Carcinoma
AkesoP1/2CC (44)
AK 127
Hepatocellular Carcinoma
AkesoP1/2CC (44)
Allo-Quadcar01-T
Diffuse Large B-Cell Lymphoma
AvenCell Therapeutics, Inc.P1/2CC (44)
Amdx-2011P
Parkinson Disease
Amydis Inc.P1/2CC (44)
Anti-Cd19/Cd22 Car-T Cells
Follicular Lymphoma
First Affiliated Hospital Xi'an Jiaotong UniversityP1/2CC (44)
Anti-Cd33 Car T-Cells
Acute Myeloid Leukemia
Zhejiang UniversityP1/2CC (44)
Anti-Flt3 Car-T
Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow UniversityP1/2CC (44)
Asidna
Metastatic Prostate Carcinoma
Valerio TherapeuticsP1/2CC (44)
Atezolizumab
Malignant Mesothelioma
Cancer Research UKP1/2CC (44)
Atezolizumab
Gastric Neoplasm
Cancer Research UKP1/2CC (44)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Plasma Cell Myeloma
Beijing BiotechP1/2CC (44)
Autologous Bcma/Gprc5D Dual-Target Car-T
B-Cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (44)
Autologous Bcma/Gprc5D Dual-Target Car-T
B-Cell Non-Hodgkin Lymphoma
Beijing BiotechP1/2CC (44)
Autologous Bcma/Gprc5D Dual-Target Car-T
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (44)
Avelumab
Non-Hodgkin Lymphoma
iOncturaP1/2CC (44)
Avelumab
Pancreatic Neoplasm
Fate TherapeuticsP1/2CC (44)
Avutometinib
Colorectal Carcinoma
University of ChicagoP1/2CC (44)
Avutometinib
Metastatic Malignant Neoplasm
Verastem, Inc.P1/2CC (44)
Axitinib
Sarcomatoid Renal Cell Carcinoma
Hao ZengP1/2CC (44)
Showing 3951 to 3975 of 6,299 assets
PreviousPage 159 of 252Next